Hautarztzentrum Dülmen on Muck Rack

Hautarztzentrum Dülmen

As seen in: Journal of The American Academy of Dermatology (JAAD)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hautarztzentrum

Contact Hautarztzentrum, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Effective treatment of actinic keratosis on the hands with red light photodynamic therapy using BF-200 ALA

|
By Martina Ulrich, Uwe Reinhold, Rolf Dominicus, Hautarztzentrum Dülmen
| tu-dresden.de
BACKGROUND: Acral actinic keratosis (AK) lesions are considered difficult to treat, and published data for photodynamic therapy (PDT) on these lesions is limited. Thus, we evaluated sustained efficacy, safety, and satisfaction after PDT for AK on the hands. METHODS: We analysed subgroup data for treatment on the hands from a randomised, double-blind, intra-individual phase III study.
Open in Who Shared Issue with article?

Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study

|
By Uwe Reinhold, Hautarztzentrum Dülmen, Martina Ulrich, Rolf Dominicus
| Journal of The American Academy of Dermatology (JAAD) Verified
Background Actinic keratoses (AK) may occur in all sun-exposed skin areas. Those occurring outside the head area are generally more resistant to treatment than those on the face. Objective To determine efficacy and safety of BF-200 ALA versus vehicle in the treatment of mild-to-severe AK located on extremities, trunk, and neck with red light photodynamic therapy (PDT). Methods This phase III study had an intra-individual design with 50 patients in 6 centers in Germany.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified